Hypermarcas (OTCMKTS:HYPMY) Short Interest Up 183.8% in July

Hypermarcas (OTCMKTS:HYPMY) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 5,807 shares, a growth of 183.8% from the June 30th total of 2,046 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 27,320 shares, the days-to-cover ratio is presently 0.2 days.

Hypermarcas Stock Performance

HYPMY opened at $3.98 on Monday. The business’s fifty day moving average is $4.15 and its two-hundred day moving average is $4.38. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 8.29 and a beta of 0.71. Hypermarcas has a one year low of $3.71 and a one year high of $5.50.

Hypermarcas (OTCMKTS:HYPMY) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. The business had revenue of $383.13 million during the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. On average, analysts predict that Hypermarcas will post 0.53 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on HYPMY. Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. Zacks Research raised shares of Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.